Total Payments
$255,155
2024 Payments
$18,968
Companies
47
Transactions
609
Medicare Patients
5,474
Medicare Billing
$1.2M
Payment Breakdown by Category
Other$168,197 (65.9%)
Consulting$45,699 (17.9%)
Travel$25,027 (9.8%)
Food & Beverage$15,475 (6.1%)
Education$756.64 (0.3%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $159,650 | 80 | 62.6% |
| Consulting Fee | $45,699 | 21 | 17.9% |
| Travel and Lodging | $25,027 | 50 | 9.8% |
| Food and Beverage | $15,475 | 435 | 6.1% |
| Current or prospective ownership or investment interest | $5,237 | 2 | 2.1% |
| Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program | $2,200 | 1 | 0.9% |
| Honoraria | $1,110 | 1 | 0.4% |
| Education | $756.64 | 15 | 0.3% |
| Unspecified | $0 | 4 | 0.0% |
Payments by Type
General
$255,155
605 transactions
Ownership
$0
4 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals Inc. | $67,687 | 95 | $0 (2024) |
| Dendreon Pharmaceuticals LLC | $45,045 | 103 | $0 (2024) |
| Janssen Scientific Affairs, LLC | $41,235 | 29 | $0 (2024) |
| Janssen Biotech, Inc. | $30,741 | 84 | $0 (2024) |
| Astellas Pharma US Inc | $18,938 | 84 | $0 (2024) |
| Myovant Sciences Inc. | $14,102 | 19 | $0 (2022) |
| PFIZER INC. | $8,893 | 34 | $0 (2024) |
| Innovative Medical Technologies, LLC | $5,237 | 6 | $0 (2020) |
| Ferring Pharmaceuticals Inc. | $3,951 | 3 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $3,318 | 11 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $18,968 | 93 | Dendreon Pharmaceuticals LLC ($9,746) |
| 2023 | $39,703 | 102 | Bayer Healthcare Pharmaceuticals Inc. ($14,533) |
| 2022 | $52,608 | 85 | Bayer HealthCare Pharmaceuticals Inc. ($19,681) |
| 2021 | $19,364 | 44 | Myovant Sciences Inc. ($5,142) |
| 2020 | $21,457 | 37 | Bayer HealthCare Pharmaceuticals Inc. ($16,840) |
| 2019 | $26,005 | 74 | Janssen Biotech, Inc. ($14,500) |
| 2018 | $36,176 | 99 | Janssen Scientific Affairs, LLC ($17,761) |
| 2017 | $40,873 | 75 | Janssen Scientific Affairs, LLC ($23,421) |
All Payment Transactions
609 individual payment records from CMS Open Payments — Page 1 of 25
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/18/2024 | Janssen Biotech, Inc. | ERLEADA (Drug) | Food and Beverage | In-kind items and services | $18.51 | General |
| Category: Oncology | ||||||
| 12/17/2024 | Sumitomo Pharma America, Inc. | ORGOVYX (Drug) | Food and Beverage | In-kind items and services | $21.83 | General |
| Category: HORMONE THERAPY | ||||||
| 12/12/2024 | AstraZeneca Pharmaceuticals LP | LYNPARZA (Drug) | Food and Beverage | In-kind items and services | $17.25 | General |
| Category: Oncology | ||||||
| 12/11/2024 | Janssen Biotech, Inc. | ERLEADA (Drug), AKEEGA | Food and Beverage | In-kind items and services | $14.12 | General |
| Category: Oncology | ||||||
| 12/05/2024 | Myriad Genetic Laboratories, Inc. | PROLARIS (Device) | Food and Beverage | In-kind items and services | $73.14 | General |
| Category: ONCOLOGY | ||||||
| 12/05/2024 | Dendreon Pharmaceuticals LLC | PROVENGE (Drug) | Food and Beverage | In-kind items and services | $31.44 | General |
| Category: CELLULAR BIOLOGIC TREATMENT FOR PROSTATE CANCER | ||||||
| 12/03/2024 | ABBVIE INC. | BOTOX (Biological) | Food and Beverage | In-kind items and services | $24.87 | General |
| Category: BOTOX THERAPEUTIC | ||||||
| 11/22/2024 | UROGEN PHARMA, INC. | — | Consulting Fee | Cash or cash equivalent | $1,562.50 | General |
| 11/21/2024 | Dendreon Pharmaceuticals LLC | PROVENGE (Drug) | Food and Beverage | In-kind items and services | $34.42 | General |
| Category: CELLULAR BIOLOGIC TREATMENT FOR PROSTATE CANCER | ||||||
| 11/18/2024 | Janssen Biotech, Inc. | ERLEADA (Drug), AKEEGA | Food and Beverage | In-kind items and services | $144.10 | General |
| Category: Oncology | ||||||
| 11/15/2024 | Dendreon Pharmaceuticals LLC | PROVENGE (Drug) | Food and Beverage | In-kind items and services | $41.28 | General |
| Category: CELLULAR BIOLOGIC TREATMENT FOR PROSTATE CANCER | ||||||
| 11/15/2024 | Bayer Healthcare Pharmaceuticals Inc. | Nubeqa (Drug) | Food and Beverage | In-kind items and services | $19.95 | General |
| Category: Oncology | ||||||
| 11/12/2024 | Novartis Pharmaceuticals Corporation | PLUVICTO (Drug) | Food and Beverage | In-kind items and services | $59.81 | General |
| Category: Oncology | ||||||
| 11/12/2024 | Janssen Biotech, Inc. | ERLEADA (Drug), AKEEGA | Food and Beverage | In-kind items and services | $18.50 | General |
| Category: Oncology | ||||||
| 11/07/2024 | UROGEN PHARMA, INC. | JELMYTO (Drug) | Food and Beverage | In-kind items and services | $16.63 | General |
| Category: UROTHELIAL CANCER | ||||||
| 11/06/2024 | Endo USA, Inc. | XIAFLEX (Biological) | Food and Beverage | In-kind items and services | $21.02 | General |
| Category: UROLOGY | ||||||
| 10/23/2024 | Dendreon Pharmaceuticals LLC | PROVENGE (Drug) | Food and Beverage | In-kind items and services | $33.64 | General |
| Category: CELLULAR BIOLOGIC TREATMENT FOR PROSTATE CANCER | ||||||
| 10/23/2024 | Sumitomo Pharma America, Inc. | ORGOVYX (Drug) | Food and Beverage | In-kind items and services | $18.89 | General |
| Category: HORMONE THERAPY | ||||||
| 10/23/2024 | Janssen Biotech, Inc. | ERLEADA (Drug), AKEEGA | Food and Beverage | In-kind items and services | $11.33 | General |
| Category: Oncology | ||||||
| 10/17/2024 | Dendreon Pharmaceuticals LLC | PROVENGE (Drug) | Food and Beverage | In-kind items and services | $34.46 | General |
| Category: CELLULAR BIOLOGIC TREATMENT FOR PROSTATE CANCER | ||||||
| 10/16/2024 | Janssen Biotech, Inc. | ERLEADA (Drug), AKEEGA | Food and Beverage | In-kind items and services | $8.20 | General |
| Category: Oncology | ||||||
| 10/10/2024 | Dendreon Pharmaceuticals LLC | PROVENGE (Drug) | Food and Beverage | In-kind items and services | $148.34 | General |
| Category: CELLULAR BIOLOGIC TREATMENT FOR PROSTATE CANCER | ||||||
| 10/03/2024 | Dendreon Pharmaceuticals LLC | PROVENGE (Drug) | Food and Beverage | In-kind items and services | $35.13 | General |
| Category: CELLULAR BIOLOGIC TREATMENT FOR PROSTATE CANCER | ||||||
| 09/26/2024 | Dendreon Pharmaceuticals LLC | PROVENGE (Drug) | Food and Beverage | In-kind items and services | $33.76 | General |
| Category: CELLULAR BIOLOGIC TREATMENT FOR PROSTATE CANCER | ||||||
| 09/25/2024 | Bayer Healthcare Pharmaceuticals Inc. | Nubeqa (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $5,279.00 | General |
| Category: Oncology | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 33 | 1,631 | 11,717 | $1.1M | $299,702 |
| 2022 | 24 | 1,253 | 11,143 | $1.0M | $276,725 |
| 2021 | 24 | 1,381 | 14,952 | $1.4M | $365,561 |
| 2020 | 22 | 1,209 | 11,837 | $1.1M | $298,297 |
Total Patients
5,474
Total Services
49,649
Medicare Billing
$1.2M
Procedure Codes
103
All Medicare Procedures & Services
103 procedure records from CMS Medicare Utilization — Page 1 of 5
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J0897 | Injection, denosumab, 1 mg | Office | 2023 | 30 | 5,220 | $321,384 | $96,856 | 30.1% |
| J9217 | Leuprolide acetate (for depot suspension), 7.5 mg | Office | 2023 | 58 | 445 | $267,903 | $60,127 | 22.4% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 289 | 379 | $109,980 | $31,253 | 28.4% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 157 | 236 | $73,092 | $29,232 | 40.0% |
| 99490 | Chronic care management services, first 20 minutes of clinical staff time directed by health care professional, per calendar month | Office | 2023 | 56 | 461 | $84,977 | $21,609 | 25.4% |
| 99426 | Principal care management services for a single high-risk disease, first 30 minutes of clinical staff time directed by health care professional, per calendar month | Office | 2023 | 39 | 246 | $44,443 | $10,930 | 24.6% |
| 99439 | Chronic care management services for two or more chronic conditions, additional 20 minutes of clinical staff time directed by health care professional, per calendar month | Office | 2023 | 51 | 164 | $22,887 | $5,776 | 25.2% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 81 | 85 | $17,227 | $4,972 | 28.9% |
| 84153 | Psa (prostate specific antigen) measurement, total | Office | 2023 | 148 | 271 | $19,063 | $4,838 | 25.4% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 40 | 40 | $17,056 | $4,234 | 24.8% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 184 | 341 | $11,052 | $2,850 | 25.8% |
| 51728 | Complex measurement of pressure of urine flow in bladder with voiding pressure studies | Office | 2023 | 15 | 15 | $11,575 | $2,618 | 22.6% |
| 99489 | Complex chronic care management services for two or more chronic conditions, each additional 60 minutes of clinical staff time directed by health care professional, per calendar month | Office | 2023 | 15 | 50 | $10,199 | $2,574 | 25.2% |
| G0416 | Surgical pathology, gross and microscopic examinations, for prostate needle biopsy, any method | Office | 2023 | 17 | 17 | $25,464 | $2,293 | 9.0% |
| 52000 | Diagnostic exam of bladder and urethra using an endoscope | Facility | 2023 | 35 | 40 | $18,412 | $2,188 | 11.9% |
| 84403 | Testosterone (hormone) level, total | Office | 2023 | 61 | 86 | $8,536 | $2,153 | 25.2% |
| 74170 | Ct scan of abdomen before and after contrast | Office | 2023 | 14 | 17 | $15,793 | $1,966 | 12.5% |
| 96402 | Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | Office | 2023 | 56 | 80 | $6,754 | $1,949 | 28.9% |
| 99487 | Complex chronic care management services for two or more chronic conditions, first 60 minutes of clinical staff time directed by health care professional, per calendar month | Office | 2023 | 15 | 20 | $7,735 | $1,899 | 24.5% |
| 55700 | Biopsy of prostate gland | Facility | 2023 | 17 | 17 | $7,527 | $1,590 | 21.1% |
| 51797 | Insertion of device into abdomen with pressure and urine flow rate study | Office | 2023 | 13 | 13 | $6,623 | $1,574 | 23.8% |
| 99427 | Principal care management services for a single high-risk disease, each additional 30 minutes of clinical staff time directed by health care professional, per calendar month | Office | 2023 | 17 | 34 | $4,725 | $1,146 | 24.3% |
| 74176 | Ct scan of abdomen and pelvis without contrast | Office | 2023 | 12 | 12 | $5,928 | $934.32 | 15.8% |
| 74018 | X-ray of abdomen, 1 view | Office | 2023 | 25 | 43 | $3,158 | $785.87 | 24.9% |
| 76770 | Complete ultrasound scan behind abdominal cavity | Office | 2023 | 15 | 15 | $4,017 | $774.19 | 19.3% |
About Dr. Benjamin Martin, MD
Dr. Benjamin Martin, MD is a Urology healthcare provider based in Gahanna, Ohio. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/17/2006. The National Provider Identifier (NPI) number assigned to this provider is 1609893221.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Benjamin Martin, MD has received a total of $255,155 in payments from pharmaceutical and medical device companies, with $18,968 received in 2024. These payments were reported across 609 transactions from 47 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($159,650).
As a Medicare-enrolled provider, Martin has provided services to 5,474 Medicare beneficiaries, totaling 49,649 services with total Medicare billing of $1.2M. Data is available for 4 years (2020–2023), covering 103 distinct procedure/service records.
Ad
Practice Information
- Specialty Urology
- Location Gahanna, OH
- Active Since 07/17/2006
- Last Updated 02/13/2020
- Taxonomy Code 208800000X
- Entity Type Individual
- NPI Number 1609893221
Products in Payments
- Nubeqa (Drug) $54,157
- PROVENGE (Drug) $48,113
- Erleada (Drug) $33,468
- DARZALEX (Biological) $23,421
- XTANDI (Drug) $14,307
- ERLEADA (Drug) $13,336
- Xofigo (Drug) $12,524
- ORGOVYX (Drug) $8,535
- Xtandi (Drug) $5,294
- LYNPARZA (Drug) $4,015
- ADSTILADRIN (Drug) $3,900
- ENZALUTAMIDE (Drug) $3,601
- NANOKNIFE (Device) $3,035
- RUBRACA (Drug) $2,962
- Axumin (Drug) $1,153
- TALZENNA (Drug) $1,110
- Non-Covered (Drug) $990.68
- ILLUCCIX (Drug) $449.50
- PYLARIFY (Drug) $383.30
- XIAFLEX (Biological) $321.30
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Urology Doctors in Gahanna
Dr. Jeffrey Carey, M.d, M.D
Urology — Payments: $17,458
Urology $17,458
Dr. Rashmi Patel, M.d, M.D
Urology — Payments: $14,054
Urology $14,054
Dr. Scott Barkin, D.o, D.O
Urology — Payments: $10,715
Urology $10,715
Dr. Linda Osborne, D.o, D.O
Urology — Payments: $10,211
Urology $10,211
Mr. Andy Cho, M.d, M.D
Urology — Payments: $10,156
Urology $10,156
Mr. Richard Klump, M.d, M.D
Urology — Payments: $9,953
Urology $9,953